TouchNEUROLOGY had the pleasure of meeting with Anthony (Tony) Traboulsee (University of British Columbia, Vancouver, Canada) to discuss the Phase 2b study investigating tolebrutinib in patients with highly active relapsing multiple sclerosis.
The abstract entitled: ‘Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the rationale for the use of tolebrutinib in MS and what are its advantages over other B-cell directed therapies? (0:13)
- What has the Phase 2b study taught us about the efficacy and safety of tolebrutinib in patients with MS? (1:17)
- Could you tell us a little about the subgroup analysis of patients with highly active relapsing MS? (2:18)
- On the basis of these findings, what will be the likely place of tolebrutinib in the treatment paradigm for MS? (3:27)
Disclosures: Anthony Traboulsee has received research grants from Roche, Sanofi Genzyme, and has personal fees from Biogen, Consortium of MS Centers, Sanofi Genzyme, Roche, Novartis, and Teva Neuroscience.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!